DBV Technologies S.A.

DBV Technologies S.A. is a clinical-stage biopharmaceutical company focused on developing epicutaneous immunotherapy (EPIT) products for food allergies. Its lead product candidate, Viaskin Peanut, has completed a Phase 3 clinical trial for the treatment of peanut allergies. The company also has Viaskin Milk, which is in Phase 1/2 clinical trials for treating IgE-mediated cow's milk protein allergy and eosinophilic esophagitis. Additionally, DBV Technologies is conducting earlier-stage research on celiac disease. The company's proprietary Viaskin technology platform delivers allergens through the skin to desensitize patients. DBV Technologies also collaborates with Nestlé Health Science on MAG1C, a ready-to-use atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers.

DBV Technologies S.A. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol DBVT. The company's shares are traded in US Dollars (USD). Although the company is headquartered in France, its listing on a US exchange allows investors to trade its stock in USD, making it accessible to a broad range of international investors.

DBV Technologies operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on researching and developing innovative therapies for food allergies. Biotechnology companies like DBV Technologies use biological processes and living organisms to create medical treatments, often involving complex research and clinical trials before products can reach the market.

DBV Technologies S.A. is headquartered in Châtillon, France. The company was incorporated in 2002 and primarily focuses on research and development activities in France. While its epicutaneous immunotherapy products target global markets, particularly for food allergies, the company's operations are centered in France. DBV Technologies collaborates with Nestlé Health Science, indicating a reach into international partnerships, but its core R&D remains in its home country.